Aerie Pharmaceuticals Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Aerie Pharmaceuticals's estimated annual revenue is currently $24.2M per year.(i)
  • Aerie Pharmaceuticals received $86.2M in venture funding in January 2018.
  • Aerie Pharmaceuticals's estimated revenue per employee is $137,392
  • Aerie Pharmaceuticals's total funding is $993.1M.

Employee Data

  • Aerie Pharmaceuticals has 176 Employees.(i)
  • Aerie Pharmaceuticals grew their employee count by -54% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care. Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialisation of first-in-class therapies for the treatment of glaucoma and other diseases of the eye. See the future of eye care with Aerie.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Aerie Pharmaceuticals's People

Project Manager, ManufacturingReveal Email/Phone
Director, Transparency and Sales OperationsReveal Email/Phone
Sr. Territory ManagerReveal Email/Phone
Territory ManagerReveal Email/Phone
Senior Director Clinical ResearchReveal Email/Phone
Senior Sales ExecutiveReveal Email/Phone
Director, Global Professional AffairsReveal Email/Phone
Director, Global Quality Systems & Lifecycle SupportReveal Email/Phone
Director, Human ResourcesReveal Email/Phone
Territory Sales ManagerReveal Email/Phone

Aerie Pharmaceuticals News

2022-04-20 - Glaucoma Therapeutics Market Size And Forecast | Inotek ...

Inotek Pharmaceuticals, Aerie pharmaceuticals Inc, Teva Pharmaceutical Industry, Bausch & Lomb Incorporated, Allergan plc, Novartis AG,...

2022-04-13 - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to ...

Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for...

2022-03-22 - Aerie Pharmaceuticals CEO discusses what's new in the ...

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for...

2019-09-08 - Durham-based Aerie Pharmaceuticals looks to raise $275M

DURHAM — Aerie Pharmaceuticals, a developer of therapies for eye diseases, has launched an offering of $250 million of convertible senior ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Aerie Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2005-10-13$21.0MAAlta Partners, Texas Pacific Group VenturesArticle
2011-03-08$30.0MBClarus Ventures, Sofinnova VenturesArticle
2013-10-28$67.0MUndisclosedRBC Capital MarketsArticle
2014-09-10$125.0MUndisclosedDeerfield Management CompanyArticle
2016-09-19$125.0MUndisclosedCantor Fitzgerald & CoArticle
2017-05-26$50.0MUndisclosedCantor Fitzgerald & Co.Article
2018-01-25$86.2MUndisclosedCantor Fitzgerald & CoArticle

Aerie Pharmaceuticals Executives

Gianluca CorbinelliChief Commercial Officer Europe
David HollanderChief R&D Officer
Raj KannanCEO
Peter LangChief Financial Officer
Casey KopczynskiChief Innovation Officer, Head of Research and External Innovation
Vicente AnidoChairman of the Board and CEO
Andrew AllenVice President, Chief Compliance Officer
Jackie HannahExecutive Assistant to COO and President
Kathleen McGinleyChief Human Resources Officer
Tom MitroPresident & COO
Peter LangChief Financial Officer
David HollanderChief Research & Development Officer
Gary SternbergChief Medical Officer
Evan HockmanVice President Sales
Tad HeitmannVice President Marketing
Christopher StatenVice President of Finance
Andrew AllenVice President, Chief Compliance Officer
Mike McCleereyVice President, Portfolio Development
Gerry McKenzieVice President, Commercial Operations
Dale SeibtVice President Market Access
Jackie HannahExecutive Assistant to COO and President
Mitchell De LongVice President, Chemistry
Ken RuettimannVP, Manufacturing
Tori ArensVice President, Drug Product Manufacturing
Tom MitroPresident & COO
Marvin GarrettGlobal Vice President, Regulatory Affairs and Quality
Karisma SharmaVice President, Global Human Resources
William CoppolaVice President, Intellectual Property
Thomas ShepardVP Implant Manufacturing Science and Technology
Finbar O'NeillVice President, Global Quality
Jeffrey CalabreseVice President Finance
Julia WilliamsVice President, Medical Affairs
Sam DinExecutive Assistant for VP of Student Services
Tom ShepardVice President, Implant Manufacturing
Jeff WhiteVice President, Research and Discovery
Mitchell de LongVice President, Chemistry